Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00557193 · OUTCOME

Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2024-07-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Proportion of cells that are viable
Interval / dispersion
Standard Deviation
Time frame
At relapse (up to 3 years)

What was measured

Described via means and standard deviations in samples which have acquired resistance to lestaurtinib

Analysis population: Arm C Dose Level 2 patients who relapsed and had data collected

Groups in this outcome

Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)

Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \>= 90 days at diagnosis and High Risk (HR) if age \< 90 days at diagnosis. Asparaginase: Given IV, IM, or PO Cyclophosphamide: Given IV Cytarabine: Given IV or IT Daunorubicin Hydrochloride: Given IV Dexamethasone: Given IV or PO Etoposide: Given IV Filgrastim: Given IV or SC Laboratory Biomarker Analysis: Correlative studies Lestaurtinib: Given PO Leucovorin Calcium: Given IV Mercaptopurine: Given PO Methotrexate: Given IV, IT, or PO Methylprednisolone: Given IV Pegaspargase: Given IM Pharmacological Study: Correlative studies Prednisone: Given PO Therapeutic Hydrocortisone: Given IT Vincristine Sulfate: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)7

Reported measurements

Source class 1
Values in Proportion of cells that are viable · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.690.15Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.15
        value
        0.69
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    units
    Participants
description
Described via means and standard deviations in samples which have acquired resistance to lestaurtinib
dispersion Type
Standard Deviation
groups
  1. description
    Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \>= 90 days at diagnosis and High Risk (HR) if age \< 90 days at diagnosis. Asparaginase: Given IV, IM, or PO Cyclophosphamide: Given IV Cytarabine: Given IV or IT Daunorubicin Hydrochloride: Given IV Dexamethasone: Given IV or PO Etoposide: Given IV Filgrastim: Given IV or SC Laboratory Biomarker Analysis: Correlative studies Lestaurtinib: Given PO Leucovorin Calcium: Given IV Mercaptopurine: Given PO Methotrexate: Given IV, IT, or PO Methylprednisolone: Given IV Pegaspargase: Given IM Pharmacological Study: Correlative studies Prednisone: Given PO Therapeutic Hydrocortisone: Given IT Vincristine Sulfate: Given IV
    id
    OG000
    title
    Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)
param Type
MEAN
population Description
Arm C Dose Level 2 patients who relapsed and had data collected
reporting Status
POSTED
time Frame
At relapse (up to 3 years)
title
Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
type
SECONDARY
unit Of Measure
Proportion of cells that are viable

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice